文献速递白血病

英国儿童B-other-ALL的FISH与MLPA双筛查遗传学特征

Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification.
PubMed 文献 · Br J Haematol · 2021-10-21

该研究采用FISH与MLPA双筛查方法,对UKALL2003试验中儿童B-other-ALL代表性队列进行特定亚群频率与长期结局分析。ABL类融合约占4%,与高MRD及未用TKI时高复发率相关;双筛查法可快速准确地将约三分之一B-other-ALL归入已知遗传亚群。

要点

  • FISH联合MLPA双筛查可快速准确地将约三分之一B-other-ALL分类为已知遗传亚群。

核心结论

  • FISH联合MLPA双筛查方法快速、准确,可常规开展,能将约三分之一B-other-ALL患者可靠归入已知遗传亚群。
  • ABL类融合约占B-other-ALL的4%,未用TKI治疗时复发率高,支持前瞻性筛查以纳入TKI。

研究设计与样本

  • 研究纳入UKALL2003儿童ALL试验中B-other-ALL代表性队列,采用FISH与MLPA双筛查方法。

主要发现

  • ZNF384、MEF2D和NUTM1重排频率较低。
  • 双筛查法可将约三分之一B-other-ALL患者可靠分类为已知遗传亚群。

临床怎么用

  • 对儿童B-other-ALL应前瞻性筛查ABL类融合,以考虑在治疗中纳入TKI。
  • FISH联合MLPA双筛查可作为常规检测,快速识别预后相关遗传亚群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While next-generation sequencing technologies provide excellent strategies to screen for newly defined genetic abnormalities of prognostic or therapeutic significance in patients with B-other-acute lymphoblastic leukaemia (ALL), they are not widely available. We used a dual screening approach, incorporating fluorescence in situ hybridisation (FISH) and Multiplex Ligation-dependent Probe Amplification (MLPA), to establish the frequency and long-term outcome of a representative cohort of specific subgroups of B-other-ALL recruited to the childhood ALL trial, UKALL2003. We focussed on abnormalities of known prognostic significance, including ABL-class fusions and ERG deletions, as a surrogate marker for DUX4-rearranged ALL. ABL-class fusions accounted for ~4% of B-other-ALL and were associated with high levels of minimal residual disease (MRD; 14/23 with MRD >5%) and a high relapse rate (55·7%) following treatment without tyrosine kinase inhibitor (TKI), confirming the importance of prospective screening with a view to incorporating TKI into therapy. Patients with deletions of ERG (~10% of B-other-ALL) had a 10-year event-free-survival of 97·2%, validating previous reports of their excellent outcome. Rearrangements of ZNF384, MEF2D and NUTM1 were observed at low frequencies. Here, we estimate that approximately one third of B-other-ALL patients can be reliably classified into one of the known genetic subgroups using our dual screening method. This approach is rapid, accurate and readily incorporated into routine testing.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Schwab CJ, Murdy D, Butler E, et al. Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification. Br J Haematol. 2021. PMID: 34676543. doi:10.1111/bjh.17869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。